Literature DB >> 31782543

The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.

James M Paik1, Rati Deshpande1, Pegah Golabi1, Issah Younossi2, Linda Henry2, Zobair M Younossi1,3.   

Abstract

BACKGROUND: Cardiovascular (CV) disease is the leading cause of mortality in patients with non-alcoholic fatty liver disease (NAFLD). The American Heart Association (AHA) developed 7 CV health metrics (poor, intermediate and ideal health) to improve CV health. AIM: To assess population-attributable fractions (PAFs) of CV health metrics to all-cause and CV mortality among NAFLD patients
METHODS: We included adult participants from National Health and Nutrition Examination Survey (NHANES 1988-1994) with clinical and mortality data. NAFLD was defined as the presence of hepatic steatosis on ultrasonography in the absence of other chronic liver diseases and excessive alcohol use.
RESULTS: A total of 4040 adults with NAFLD and 7515 without were included. NAFLD had fewer ideal health metrics than non-NAFLD (age-standardised prevalence: 20% vs 10% for ≤1 ideal health metric; 5.1% vs 8.7% for ≥6, all P < .001). Following median follow-up of 19.2 years (IQR: 17.5-21.0 years), 1,136 NAFLD subjects (327 CV deaths) and 1600 non-NAFLD subjects (447 CV deaths) died. Increased number of ideal health metrics (all trend P < .0001) correlated with lower risk for all-cause and CV mortality. If all NAFLD subjects achieved 7 ideal health metrics, 66% of all-cause deaths and 83% of CV deaths were preventable. Among NAFLD subjects, lack of glycaemic control (adjusted PAF = 28.3% all-cause; 38.1% CV) and hypertension (adjusted PAF of 23% all-cause; 52.8% CV) were the largest mortality contributors. Ideal physical activity level obtainment provided an adjusted PAF = 13.9% all-cause and 13.8% CV mortality.
CONCLUSIONS: Attainment of ideal CV health metrics provides protection against all-cause and CV deaths in NAFLD.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31782543     DOI: 10.1111/apt.15580

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

2.  Interrelationship between physical activity and depression in nonalcoholic fatty liver disease.

Authors:  Ali A Weinstein; Leyla De Avila; Saisruthi Kannan; James M Paik; Pegah Golabi; Lynn H Gerber; Zobair M Younossi
Journal:  World J Hepatol       Date:  2022-03-27

3.  Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Nicole Cianci; Mohsan Subhani; Trevor Hill; Amardeep Khanna; Dong Zheng; Abhishek Sheth; Colin Crooks; Guruprasad P Aithal
Journal:  World J Hepatol       Date:  2022-05-27

4.  NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.

Authors:  Jiyoon Park; Eunice Yewon Lee; Jie Li; Mi Jung Jun; Eileen Yoon; Sang Bong Ahn; Chuanli Liu; Hongli Yang; Fajuan Rui; Biyao Zou; Linda Henry; Dong Hyun Lee; Dae Won Jun; Ramsey C Cheung; Mindie H Nguyen
Journal:  Dig Dis       Date:  2021-02-03       Impact factor: 2.404

5.  Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.

Authors:  Magnus Holmer; Catarina Lindqvist; Sven Petersson; John Moshtaghi-Svensson; Veronika Tillander; Torkel B Brismar; Hannes Hagström; Per Stål
Journal:  JHEP Rep       Date:  2021-02-17

6.  Dietary linoleic acid and the ratio of unsaturated to saturated fatty acids are inversely associated with significant liver fibrosis risk: A nationwide survey.

Authors:  Tingting Zhu; Xiao-Ting Lu; Zhao-Yan Liu; Hui-Lian Zhu
Journal:  Front Nutr       Date:  2022-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.